Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MRK
stocks logo

MRK

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
16.18B
+3.57%
2.045
+18.91%
16.00B
+3.06%
1.646
-25.87%
16.52B
+4.54%
2.227
+4.56%
Estimates Revision
The market is revising Upward the revenue expectations for Merck & Co., Inc. (MRK) for FY2025, with the revenue forecasts being adjusted by 0.15% over the past three months. During the same period, the stock price has changed by 19.10%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.15%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.04%
In Past 3 Month
Stock Price
Go Up
up Image
+19.10%
In Past 3 Month
Wall Street analysts forecast MRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRK is 104.40 USD with a low forecast of 82.00 USD and a high forecast of 139.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast MRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRK is 104.40 USD with a low forecast of 82.00 USD and a high forecast of 139.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
8 Hold
0 Sell
Moderate Buy
Current: 100.890
sliders
Low
82.00
Averages
104.40
High
139.00
Current: 100.890
sliders
Low
82.00
Averages
104.40
High
139.00
BNP Paribas Exane
Underperform -> Outperform
upgrade
€145
2025-12-02
New
Reason
BNP Paribas Exane
Price Target
€145
2025-12-02
New
upgrade
Underperform -> Outperform
Reason
BNP Paribas Exane upgraded Merck KGaA to Outperform from Underperform with a EUR 145 price target.
Goldman Sachs
Asad Haider
maintain
$92 -> $120
2025-12-02
New
Reason
Goldman Sachs
Asad Haider
Price Target
$92 -> $120
2025-12-02
New
maintain
Reason
Goldman Sachs analyst Asad Haider raised the firm's price target on Merck to $120 from $92 and keeps a Buy rating on the shares.
Wells Fargo
Equal Weight -> Overweight
upgrade
$90 -> $125
2025-11-24
Reason
Wells Fargo
Price Target
$90 -> $125
2025-11-24
upgrade
Equal Weight -> Overweight
Reason
Wells Fargo upgraded Merck to Overweight from Equal Weight with a price target of $125, up from $90. Following recent business development, pipeline progress, and new launches, the firm sees Merck filling the shortfall from Keytruda LOE and growing revenue in the early 2030s. The company is entering a catalyst rich period in the next 12-18 months with readouts across its pipeline, Wells argues.
Scotiabank
Outperform
initiated
$105
2025-11-12
Reason
Scotiabank
Price Target
$105
2025-11-12
initiated
Outperform
Reason
Scotiabank initiated coverage of Merck with an Outperform rating and $105 price target.
Morgan Stanley
Terence Flynn
Equal Weight
maintain
$98 -> $100
2025-11-03
Reason
Morgan Stanley
Terence Flynn
Price Target
$98 -> $100
2025-11-03
maintain
Equal Weight
Reason
Morgan Stanley analyst Terence Flynn raised the firm's price target on Merck to $100 from $98 and keeps an Equal Weight rating on the shares. Q3 results beat expectations, but driven by one-timers and Januvia as Keytruda and Winrevair came in below expectations, the analyst tells investors. Merck guided to "solid" top line growth in 2026 from new launches, but also highlighted an acceleration in operating expense, notes the analyst, who models 2026 EPS of $9.44.
Benchmark
analyst
Buy
upgrade
$75 -> $90
2025-09-24
Reason
Benchmark
analyst
Price Target
$75 -> $90
2025-09-24
upgrade
Buy
Reason
Benchmark raised the firm's price target on Halozyme (HALO) to $90 from $75 and keeps a Buy rating on the shares. The FDA has approved Merck's (MRK) subcutaneous Keytruda Qlex, a large oncology drug that includes berahyaluronidase alpha-pmph, an enzyme licensed from Korean firm Alteogen that competes with Halozyme's Enhanze enzyme, the analyst noted. The pending launch of SubQ Keytruda is expected to bring to a head the ongoing patent litigation between Halozyme and Merck, the analyst added.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Merck & Co Inc (MRK.N) is 12.15, compared to its 5-year average forward P/E of 16.88. For a more detailed relative valuation and DCF analysis to assess Merck & Co Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
16.88
Current PE
12.15
Overvalued PE
31.66
Undervalued PE
2.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
11.57
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
16.60
Undervalued EV/EBITDA
6.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.07
Current PS
0.00
Overvalued PS
4.66
Undervalued PS
3.48
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 278.89% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areSelling! The selling amount has increased103.13%over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 278.89% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MRK News & Events

Events Timeline

(ET)
2025-12-04
13:30:00
Halozyme Secures Preliminary Injunction Against Merck's Keytruda SC Sales in Germany
select
2025-12-04
12:10:00
Merck Animal Health Receives Conditional FDA Approval for EXZOLT CATTLE-CA1
select
2025-12-04
10:20:00
FDA Plans to Reduce Drug Approval Trials, Shares of Icon and Others Drop
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
08:00 AMNASDAQ.COM
PinnedMerck Division Receives FDA Conditional Approval for EXZOLT CATTLE-CA1 to Address Major Cattle Parasites

  • FDA Approval: Merck Animal Health has received conditional approval from the FDA for EXZOLT CATTLE-CA1, a topical solution effective against New World screwworm larvae and cattle fever ticks.

  • Product Details: EXZOLT CATTLE-CA1 is a pour-on solution containing fluralaner, approved for beef cattle over two months old and replacement dairy heifers under 20 months, with a 98-day meat withdrawal period.

  • Market Availability: The product will be available by prescription in 1 L or 5 L sizes starting in the first quarter of 2026, with restrictions on off-label use.

  • International Authorization: Merck has also received market authorization in Mexico for EXZOLT CATTLE-CA1 to help control the spread of New World screwworm in cattle.

[object Object]
Preview
4.5
05:00 AMNASDAQ.COM
Most Active Stocks After Hours on December 4, 2025: AVPT, NVDA, CMCSA, INTC, KO, WMB, GM, DIS, MRK, AMZN, AAPL, BSX

  • NASDAQ 100 After Hours Performance: The NASDAQ 100 After Hours Indicator is down -2.19 to 25,579.51, with a total after-hours volume of 122,958,176 shares traded.

  • Active Stocks Overview: AvePoint, NVIDIA, Comcast, Intel, Coca-Cola, Williams Companies, General Motors, Walt Disney, Merck, Amazon, Apple, and Boston Scientific are among the most active stocks in after-hours trading, with various price changes and trading volumes.

  • Stock Recommendations: Most of the mentioned stocks, including AvePoint, NVIDIA, Coca-Cola, Williams Companies, Walt Disney, Merck, Amazon, and Apple, have a current mean recommendation in the "buy range" according to Zacks.

  • Earnings Forecasts: Notable companies like NVIDIA and Walt Disney have had recent revisions in their earnings forecasts, with NVIDIA's consensus EPS forecast at $1.42 and Disney's at $1.78 for upcoming fiscal quarters.

[object Object]
Preview
9.0
02:53 AMBenzinga
Combination of Pliant Cancer Drug and Merck's Keytruda Enhances Treatment Responses in Challenging Tumors

  • Pliant Therapeutics' Trial Results: Pliant Therapeutics released promising interim data from its Phase 1 trial of PLN-101095, showing antitumor activity in combination with Merck's Keytruda in patients with advanced solid tumors that are refractory to immune checkpoint inhibitors.

  • Clinical Responses Observed: Among the heavily pretreated patient population, there were four responders, including one complete response and three partial responses, with clinical responses noted in various cancer types such as cholangiocarcinoma and melanoma.

  • IFN-γ Levels and Tolerability: Responding patients exhibited significant increases in plasma interferon gamma levels, while PLN-101095 was generally well tolerated, demonstrating a dose-dependent pharmacokinetic profile.

  • Stock Performance and Future Plans: Despite the positive trial results, Pliant's stock fell by over 20%, trading near its 52-week low, while the company plans to initiate a Phase 1b trial in 2026 to further explore PLN-101095's efficacy in non-small cell lung cancer and other tumor types.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Merck & Co Inc (MRK) stock price today?

The current price of MRK is 100.89 USD — it has decreased -1.35 % in the last trading day.

arrow icon

What is Merck & Co Inc (MRK)'s business?

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

arrow icon

What is the price predicton of MRK Stock?

Wall Street analysts forecast MRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRK is 104.40 USD with a low forecast of 82.00 USD and a high forecast of 139.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Merck & Co Inc (MRK)'s revenue for the last quarter?

Merck & Co Inc revenue for the last quarter amounts to 17.28B USD, increased 3.72 % YoY.

arrow icon

What is Merck & Co Inc (MRK)'s earnings per share (EPS) for the last quarter?

Merck & Co Inc. EPS for the last quarter amounts to 2.32 USD, increased 87.10 % YoY.

arrow icon

What changes have occurred in the market's expectations for Merck & Co Inc (MRK)'s fundamentals?

The market is revising Upward the revenue expectations for Merck & Co., Inc. (MRK) for FY2025, with the revenue forecasts being adjusted by 0.15% over the past three months. During the same period, the stock price has changed by 19.10%.
arrow icon

How many employees does Merck & Co Inc (MRK). have?

Merck & Co Inc (MRK) has 75000 emplpoyees as of December 05 2025.

arrow icon

What is Merck & Co Inc (MRK) market cap?

Today MRK has the market capitalization of 250.41B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free